Various challenges still surround the use of cancer biologics, but expert guidance and expiring patents may help expand their use and benefits.
A study shows stage III renal cell carcinoma patients with nodal disease may need to be reclassified.
A study shows RCC patients overall response rate did not decline from the first‐line to the fourth‐line of IO therapy.
A subgroup analysis of Short-HER looked at the differences in 5-year DFS rates for 9 weeks vs 1 year of trastuzumab for HER2+ breast cancer patients.
Evaluating the prognostic value of PET-CT responses after first-line immunochemotherapy in follicular lymphoma.
Research presented this week at ESMO studied the efficacy of biosimilars to trastuzumab compared with the reference product in breast cancer.
Researchers tested whether combining chemotherapy with immunotherapy would offer improved survival for patients with triple-negative breast cancer.
In this study, researchers evaluated changes in CVD risk factors and 10-year CVD risk from before to after a breast cancer diagnosis, and compared it with women who remained free of such a diagnosis.
Professor Han Liang speaks with Cancer Network about the ubiquitin pathway and its role in cancer research.
A new study evaluated whether busulfan and melphalan improve EFS and OS when given after vincristine, ifosfamide, doxorubicin, and etoposide induction.